Key result
Age-based clopidogrel dose escalation may benefit pediatric cardiac patients 0-24 months over static low dosing.
Why the study?
Pediatric cardiac patients may require gradual escalation of clopidogrel dosing with age, contrasting with the static low dose recommended by the PICOLO trial during the first 24 months of life.
Does an age-based clopidogrel dosing scheme provide better therapeutic effect than a static low dose in pediatric cardiac patients 0-24 months old?
Does an age-based clopidogrel dosing scheme provide better therapeutic effect than a static low dose in pediatric cardiac patients 0-24 months old?
An age-based clopidogrel dosing scheme may be necessary for pediatric cardiac patients 0-24 months old, challenging the current static low-dose recommendation.
Hypothesis-generating for age-based dosing in infants; challenges PICOLO static-dose consensus but requires RCTs before practice change.
Pediatric cardiac patients may require a gradual escalation of clopidogrel dosing with age, in contrast to the static low dose recommended by the PICOLO trial during the first 24 months of life. An age-based dosing scheme may prove beneficial for this age group. Prospective studies evaluating age-based clopidogrel dosing in this patient population could offer further insight into this relationship.
No takes yet. Share an insight, caveat, or question.
Anton-Martin et al. (2026) studied this question. An age-based clopidogrel dosing scheme may be beneficial for pediatric cardiac patients 0-24 months, suggesting dose escalation with age instead of static low dose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: